159 related articles for article (PubMed ID: 15147806)
1. In vivo and in vitro evaluation of three controlled release principles of 6-N-cyclohexyl-2'-O-methyladenosine.
Royce A; Li S; Weaver M; Shah U
J Control Release; 2004 May; 97(1):79-90. PubMed ID: 15147806
[TBL] [Abstract][Full Text] [Related]
2. Preparation and in vitro/in vivo evaluation of sustained-release metformin hydrochloride pellets.
Hu LD; Liu Y; Tang X; Zhang Q
Eur J Pharm Biopharm; 2006 Oct; 64(2):185-92. PubMed ID: 16797948
[TBL] [Abstract][Full Text] [Related]
3. Preparation and in vitro-in vivo evaluation of double layer coated and matrix sustained release pellet formulations of diclofenac potassium.
Fu J; Wang X; Xu L; Meng J; Weng Y; Li G; He H; Tang X
Int J Pharm; 2011 Mar; 406(1-2):84-90. PubMed ID: 21219996
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo evaluation of two extended release preparations of combination metformin and glipizide.
Defang O; Shufang N; Wei L; Hong G; Hui L; Weisan P
Drug Dev Ind Pharm; 2005 Aug; 31(7):677-85. PubMed ID: 16207615
[TBL] [Abstract][Full Text] [Related]
5. Dosage form design and in vitro/in vivo evaluation of cevimeline extended-release tablet formulations.
Tajiri S; Kanamaru T; Kamada M; Konno T; Nakagami H
Int J Pharm; 2010 Jan; 383(1-2):99-105. PubMed ID: 19747964
[TBL] [Abstract][Full Text] [Related]
6. Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels.
Deshpande MC; Venkateswarlu V; Babu RK; Trivedi RK
Int J Pharm; 2009 Oct; 380(1-2):16-24. PubMed ID: 19563873
[TBL] [Abstract][Full Text] [Related]
7. Influence of dissolution media composition on drug release and in-vitro/in-vivo correlation for paracetamol matrix tablets prepared with novel carbomer polymers.
Parojcić J; Ethurić Z; Jovanović M; Ibrić S; Jovanović D
J Pharm Pharmacol; 2004 Jun; 56(6):735-41. PubMed ID: 15231038
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo evaluation of tegaserod maleate pH-dependent tablets.
Zhang SQ; Thumma S; Chen GH; Deng WB; Repka MA; Li SM
Eur J Pharm Biopharm; 2008 May; 69(1):247-54. PubMed ID: 18037278
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of different release apparatus in generating in vitro-in vivo correlations for extended release formulations.
Fotaki N; Aivaliotis A; Butler J; Dressman J; Fischbach M; Hempenstall J; Klein S; Reppas C
Eur J Pharm Biopharm; 2009 Sep; 73(1):115-20. PubMed ID: 19442728
[TBL] [Abstract][Full Text] [Related]
10. Formulation, release characteristics and bioavailability of novel monolithic hydroxypropylmethylcellulose matrix tablets containing acetaminophen.
Cao QR; Choi YW; Cui JH; Lee BJ
J Control Release; 2005 Nov; 108(2-3):351-61. PubMed ID: 16154656
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets.
Hayashi T; Kanbe H; Okada M; Kawase I; Ikeda Y; Onuki Y; Kaneko T; Sonobe T
Int J Pharm; 2007 Aug; 341(1-2):105-13. PubMed ID: 17512147
[TBL] [Abstract][Full Text] [Related]
12. Development and biopharmaceutical evaluation of extended release formulation of tramadol hydrochloride based on osmotic technology.
Kumar P; Singh S; Mishra B
Acta Pharm; 2009 Mar; 59(1):15-30. PubMed ID: 19304555
[TBL] [Abstract][Full Text] [Related]
13. Formulation of sustained - release lithium carbonate matrix tablets: influence of hydrophilic materials on the release rate and in vitro-in vivo evaluation.
Emami J; Tavakoli N; Movahedian A
J Pharm Pharm Sci; 2004 Nov; 7(3):338-44. PubMed ID: 15576014
[TBL] [Abstract][Full Text] [Related]
14. Theophylline controlled-release formulations: in vivo-in vitro correlations.
Yu Z; Schwartz JB; Sugita ET
Biopharm Drug Dispos; 1996 Apr; 17(3):259-72. PubMed ID: 8983400
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo evaluation of ofloxacin sustained release pellets.
Cui Y; Zhang Y; Tang X
Int J Pharm; 2008 Aug; 360(1-2):47-52. PubMed ID: 18538518
[TBL] [Abstract][Full Text] [Related]
16. In-vitro and in-vivo correlation for two gliclazide extended-release tablets.
Mandal U; Ray KK; Gowda V; Ghosh A; Pal TK
J Pharm Pharmacol; 2007 Jul; 59(7):971-6. PubMed ID: 17637192
[TBL] [Abstract][Full Text] [Related]
17. Two different approaches for the prediction of in vivo plasma concentration-time profile from in vitro release data of once daily formulations of diltiazem hydrochloride.
Bendas ER
Arch Pharm Res; 2009 Sep; 32(9):1317-29. PubMed ID: 19784589
[TBL] [Abstract][Full Text] [Related]
18. Leaky enteric coating on ranitidine hydrochloride beads: dissolution and prediction of plasma data.
Bendas ER; Ayres JW
Eur J Pharm Biopharm; 2008 Aug; 69(3):977-85. PubMed ID: 18424095
[TBL] [Abstract][Full Text] [Related]
19. Time-release compression-coated core tablet containing nifedipine for chronopharmacotherapy.
Sawada T; Kondo H; Nakashima H; Sako K; Hayashi M
Int J Pharm; 2004 Aug; 280(1-2):103-11. PubMed ID: 15265551
[TBL] [Abstract][Full Text] [Related]
20. Time-controlled release pseudoephedrine tablets: bioavailability and in vitro/in vivo correlations.
Halsas M; Penttinen T; Veski P; Jürjenson H; Marvola M
Pharmazie; 2001 Sep; 56(9):718-23. PubMed ID: 11593992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
